Header cover image

Taiwanese (TAIEX) Clinical Research and Equipment Industry Analysis

UpdatedJul 21, 2024
DataAggregated Company Financials
Companies9
  • 7D-1.4%
  • 3M13.1%
  • 1Y-14.8%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.6%, driven by Locus Cell declining 9.2%. The industry has fallen 13% in the last year. Looking forward, earnings are forecast to grow by 2.4% annually.

Industry Valuation and Performance

Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 21 Jul 2024NT$43.3bNT$2.1b-NT$797,765,000.0033.6x-54.3x20.3x
Tue, 18 Jun 2024NT$41.8bNT$2.1b-NT$797,765,000.0033.7x-52.4x19.6x
Thu, 16 May 2024NT$40.1bNT$2.1b-NT$893,893,000.0031.9x-44.8x18.8x
Sat, 13 Apr 2024NT$40.9bNT$2.1b-NT$903,875,000.0030.9x-45.3x19.4x
Mon, 11 Mar 2024NT$41.7bNT$2.1b-NT$611,249,000.0032.5x-68.3x20.2x
Wed, 07 Feb 2024NT$43.0bNT$2.1b-NT$610,218,000.0032.4x-70.4x20.7x
Fri, 05 Jan 2024NT$47.5bNT$2.1b-NT$610,218,000.0034.5x-77.9x22.9x
Sun, 03 Dec 2023NT$48.8bNT$2.1b-NT$610,218,000.0033.4x-80x23.5x
Tue, 31 Oct 2023NT$49.8bNT$2.2b-NT$497,769,000.0031.7x-100.1x22.4x
Thu, 28 Sep 2023NT$48.2bNT$2.2b-NT$497,769,000.0030.8x-96.9x21.7x
Sat, 26 Aug 2023NT$43.1bNT$2.2b-NT$497,769,000.0031.3x-86.5x19.4x
Mon, 24 Jul 2023NT$48.1bNT$2.5b-NT$274,767,000.0043.1x-175.2x19.6x
Wed, 21 Jun 2023NT$49.0bNT$2.5b-NT$274,767,000.0043.2x-178.4x20x
Fri, 19 May 2023NT$50.9bNT$2.6b-NT$38,534,000.0042x-1320x19.4x
Sun, 16 Apr 2023NT$51.1bNT$2.7b-NT$29,761,000.0024.7x-1715.9x19.2x
Tue, 14 Mar 2023NT$48.0bNT$2.7bNT$82.4m24.1x582.7x18.1x
Thu, 09 Feb 2023NT$52.2bNT$2.7bNT$85.3m20x612x19.5x
Sat, 07 Jan 2023NT$47.8bNT$2.7bNT$85.3m18.6x560.2x17.9x
Mon, 05 Dec 2022NT$57.7bNT$2.7bNT$139.5m18.6x413.6x21.6x
Wed, 02 Nov 2022NT$42.3bNT$3.0bNT$482.8m24.4x87.6x14.1x
Fri, 30 Sep 2022NT$43.8bNT$3.0bNT$482.8m23.7x90.7x14.6x
Sun, 28 Aug 2022NT$50.0bNT$3.0bNT$482.8m28.1x103.5x16.7x
Tue, 26 Jul 2022NT$41.4bNT$3.1bNT$325.1m37.8x127.3x13.5x
Thu, 23 Jun 2022NT$40.6bNT$3.1bNT$325.1m36.3x124.9x13.2x
Sat, 21 May 2022NT$29.9bNT$3.1bNT$325.1m35x91.8x9.7x
Mon, 18 Apr 2022NT$36.5bNT$3.2bNT$164.4m28.1x222.2x11.5x
Wed, 16 Mar 2022NT$32.4bNT$3.0b-NT$115,919,000.0025.2x-279.2x10.6x
Fri, 11 Feb 2022NT$37.0bNT$3.0b-NT$120,147,000.0035.3x-307.9x12.1x
Sun, 09 Jan 2022NT$38.0bNT$3.0b-NT$120,147,000.0036.2x-315.9x12.5x
Tue, 07 Dec 2021NT$39.3bNT$3.0b-NT$120,147,000.0037.3x-327.4x12.9x
Thu, 04 Nov 2021NT$30.3bNT$2.8b-NT$511,386,000.0023.2x-59.2x10.7x
Sat, 02 Oct 2021NT$34.7bNT$2.3b-NT$631,150,000.0031.8x-55x14.9x
Mon, 30 Aug 2021NT$35.7bNT$2.3b-NT$631,150,000.0032.1x-56.6x15.4x
Price to Earnings Ratio

-62.5x


Total Market Cap: NT$39.5bTotal Earnings: -NT$631,150,000.00Total Revenue: NT$2.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Clinical Research and Equipment Industry Price to Earnings3Y Average -90.3x202220232024
Current Industry PE
  • Investors are optimistic on the Taiwanese Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 17.0x is lower than the industry's current PS ratio of 20.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
  • Revenues have also declined 2.8% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Comparison

How does Taiwanese Clinical Research and Equipment compare with similar industries?

TW Market-4.14%
Healthcare1.15%
Life Sciences-1.43%
Clinical Research and Equipment-1.43%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6661 Welgene BiotechLtdNT$35.8523.4%
+NT$158.5m
54.9%PS2.8x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6662

NT$39.25

BioLASCO Taiwan

7D

-0.4%

1Y

19.7%

6891

NT$29.10

Locus Cell

7D

-5.7%

1Y

-16.7%

6589

NT$90.50

EirGenix

7D

-0.8%

1Y

-16.2%

4133

NT$33.10

Abnova (Taiwan)

7D

-1.0%

1Y

-4.5%

6661

NT$35.85

Welgene BiotechLtd

7D

23.4%

1Y

54.9%

6848

NT$18.55

RBC Bioscience

7D

-0.3%

1Y

8.5%

6939

NT$39.95

TFBS Bioscience

7D

-2.9%

1Y

-32.2%

6986

NT$71.80

HeXun Biosciences

7D

-3.4%

1Y

n/a

7607

NT$32.30

DuoGenic StemCells

7D

-3.9%

1Y

-14.0%